Livestock Vaccine MarketSize, Share & Industry Analysis, 2026-2034By Animal TypeBy Vaccine TypeBy Disease/indicationBy Route of AdministrationBy Distribution Channel
Full title & scope — all 5 axes with their segments
Livestock Vaccine Market Size, Share & Industry Analysis, By Animal Type (Poultry, Swine, Cattle, Sheep & Goat, Aquaculture, Other Livestock), By Vaccine Type (Live Attenuated, Inactivated / Killed, Toxoid, Recombinant / Subunit, DNA & Vector-based), By Disease/indication (Avian Influenza & Newcastle Disease, Foot-and-Mouth Disease, Bovine Respiratory Disease Complex, Porcine Reproductive & Respiratory Syndrome, Other Diseases), By Route of Administration (Injectable, Spray / Aerosol, Oral, In-ovo), By Distribution Channel (Veterinary Hospitals & Clinics, Retail & Farm Supply Stores, Online & Direct-to-Farm), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By Animal TypePoultry · Swine · Cattle
- 02By Vaccine TypeLive Attenuated · Inactivated / Killed · Toxoid
- 03By Disease/indicationAvian Influenza & Newcastle Disease · Foot-and-Mouth Disease · Bovine Respiratory Disease Complex
- 04By Route of AdministrationInjectable · Spray / Aerosol · Oral
- 05By Distribution ChannelVeterinary Hospitals & Clinics · Retail & Farm Supply Stores · Online & Direct-to-Farm
- 06By Region
Market Analysis & Outlook
Livestock vaccines are biological products administered to farm animals, including poultry, swine, cattle, sheep, goats and farmed aquatic species, to prevent or control infectious and parasitic diseases before they spread through a herd or flock. They are formulated as live attenuated, inactivated, toxoid, subunit or vector-based products and delivered by injection, oral dosing, spray or in-ovo application depending on the species and disease targeted. Buyers span integrated poultry and swine producers, individual cattle and small ruminant farmers, aquaculture operators, veterinary practices and government animal health agencies running compulsory disease-control programs.
Growth of 6.93% a year carries the global livestock vaccine market from USD 6.85 billion in 2025 to USD 12.48 billion in 2034. The full series behind that rate covers USD 5.05 billion in 2020, USD 6.43 billion in 2024, USD 7.3 billion in 2026 and USD 9.51 billion in 2030, with 2025 as the base year.
Composition changes more than the total does. Aquaculture, at 11.06%, outgrows Swine at 6.36%, and its share moves from 7.01% to 10.02%. Poultry stays the largest line throughout, at USD 2.33 billion in 2025 and USD 4.12 billion in 2034. The lines gaining share are Aquaculture and Other Livestock (Equine & Others). Poultry, Swine, Cattle (Bovine) and Sheep & Goat (Ovine/Caprine) lose share without losing revenue.
By vaccine type, Live Attenuated accounts for 37.96% of 2025 revenue at USD 2.6 billion, reaching USD 4.24 billion and 34% by 2034. DNA & Vector-based grows faster at 11.81% against 5.58%, moving from 5.99% of revenue to 8.98% by 2034. This axis divides the same revenue as the animal type split instead of adding to it, so the two are read together and never summed.
The regional order runs from Asia Pacific at 32% of 2025 revenue down to Middle East and Africa at 7%. Asia Pacific is worth USD 2.19 billion in 2025 and USD 4.37 billion in 2034; North America, second at 24%, moves from USD 1.64 billion to USD 2.62 billion. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates instead of spreading across all five regions.
Coverage extends to five regions, six animal type lines and five segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global livestock vaccine market moves from USD 5.05 billion in 2020 to USD 6.85 billion in 2025 and USD 12.48 billion by 2034, the forecast period compounding at 6.93% a year.
- 34.01% of 2025 revenue sits in Poultry (USD 2.33 billion) and it remains the largest animal type line in 2034 at USD 4.12 billion and 33.01%.
- Aquaculture is the fastest-growing line at 11.06%, lifting its share from 7.01% in 2025 to 10.02% in 2034 and its revenue from USD 0.48 billion to USD 1.25 billion.
- Scenario range for 2034 runs from USD 11.48 billion in the bear case to USD 13.48 billion in the bull case, against a base-case USD 12.48 billion, the spread a plan built on this forecast has to absorb.
- Asia Pacific holds 32% of global revenue in 2025 at USD 2.19 billion, the largest of the five regions tracked, and reaches USD 4.37 billion by 2034.
- 34% of Asia Pacific's base-year revenue comes from China alone: USD 0.74 billion in 2025, rising to USD 1.49 billion by 2034, which is why it is that region's worked example.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By By Animal Type
Base year 2025Poultry leads with 34.0% of by animal type segment revenue.
Share of by animal type segment revenue, most recent base year.
Read across the forecast period, the global livestock vaccine market shows movement in three places: animal type composition, regional weight, and the 6.93% rate applied to the whole.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
The animal type mix tilts toward Aquaculture. 11.06% against 6.36%: that gap, between Aquaculture and Swine, is the largest on the animal type axis. Shares follow: 7.01% to 10.02% for Aquaculture, 22.04% to 20.99% for Swine. In absolute terms Aquaculture rises from USD 0.48 billion to USD 1.25 billion, while Swine rises from USD 1.51 billion to USD 2.62 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 32% of revenue in 2025 to 35% in 2034, worth USD 2.19 billion rising to USD 4.37 billion; Latin America moves from 15% of revenue in 2025 to 17% in 2034, worth USD 1.03 billion rising to USD 2.12 billion; Middle East and Africa moves from 7% of revenue in 2025 to 8% in 2034, worth USD 0.48 billion rising to USD 1 billion. Against that, North America at 24% moving to 21%, Europe at 22% moving to 19%, a fall in share, not in revenue. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
Growth compounds at 6.93% without a step change. Reading the series: USD 5.05 billion in 2020, USD 6.43 billion in 2024, USD 6.85 billion in 2025, USD 7.3 billion in 2026, USD 9.51 billion in 2030 and USD 12.48 billion in 2034. The forecast rate of 6.93% sits against 6.29% over the historical period, so the projection extends an observed trend instead of proposing a new one. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the animal type and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Aquaculture adds the most incremental growth
Market Drivers
3- 01Aquaculture adds the most incremental growth
The fastest line on the animal type axis is Aquaculture, at 11.06% against the market's 6.93%, taking USD 0.48 billion to USD 1.25 billion and 7.01% of revenue to 10.02%. Because the spread to Swine at 6.36% is this wide, the headline 6.93% is a weighted result, not a rate any single line achieves. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02Regional weight, not regional count
32% of 2025 revenue (USD 2.19 billion) is generated in Asia Pacific, reaching USD 4.37 billion by 2034, with share rising to 35%. Behind it, North America holds 24%; USD 1.64 billion rising to USD 2.62 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03Fifteen years of unbroken growth underpin the forecast
Revenue rose through USD 5.05 billion in 2020, USD 6.43 billion in 2024 and USD 6.85 billion in 2025, a compound 6.29% across the historical period. The forecast period then runs at 6.93%, ending 2034 at USD 12.48 billion. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix, not the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising global protein demand expanding herd and flock size | High | +1.7 | High | High | High |
| 2 | Disease outbreak response and compulsory vaccination mandates | High | +1.55 | High | Medium | Medium |
| 3 | Intensification of livestock production and biosecurity investment | Medium-High | +1.1 | Medium | High | High |
| 4 | Aquaculture expansion and rising uptake of aquaculture vaccination | Medium-High | +0.85 | Low | Medium | High |
| 5 | Expansion of veterinary vaccination infrastructure in emerging markets | Medium | +0.6 | Low | Medium | Medium |
| 6 | Others | Low | +0.3 | Low | Low | Low |
| Total | +6.1 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Cold-chain and logistics constraints in developing regions | Medium | −0.25 | Medium | Medium | Low |
| 2 | Price sensitivity among smallholder and subsistence farmers | Medium | −0.15 | Medium | Medium | Medium |
| 3 | Regulatory approval timelines for new vaccine platforms | Low | −0.07 | Low | Low | Low |
| Total | −0.47 | |||||
Drivers contribute 6.1 Billion and restraints remove 0.47 Billion, a net 5.63 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global livestock vaccine market comes from three measurable sources over 2026-2034: the market's own compounding at 6.93%, the share gained by faster-growing animal type lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Bear assumes slower herd and flock expansion, constrained public budgets for compulsory vaccination programs, and delayed adoption of newer vaccine platforms among smallholder and subsistence livestock operations. On that assumption 2034 revenue lands at USD 11.48 billion against the USD 12.48 billion base case, from the same USD 6.85 billion 2025 starting point.
- 02The largest line is not the fastest
Poultry carries 34.01% of 2025 revenue at USD 2.33 billion but compounds at 6.6% against 6.93% for the market, taking its share to 33.01% by 2034 even as revenue rises to USD 4.12 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
A bull case of USD 13.48 billion by 2034, against USD 12.48 billion in the base case, turns on a single stated assumption: bull assumes faster adoption of recombinant and vector-based vaccine platforms, sustained outbreak-driven mass immunization campaigns, and accelerated public and private investment in vaccination infrastructure across emerging livestock-producing regions. The USD 6.85 billion 2025 base is common to both.
- 02Aquaculture share moves from 7.01% to 10.02%
Aquaculture grows at 11.06% against 6.93% for the market, adding revenue from USD 0.48 billion in 2025 to USD 1.25 billion in 2034 and taking its share from 7.01% to 10.02%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Poultry.
Market Challenges
Revenue is concentrated in Poultry
Market Challenges
2- 01Revenue is concentrated in Poultry
USD 2.33 billion of 2025 revenue sits in Poultry, 34.01% of the total, and it is still 33.01% at USD 4.12 billion nine years later. A market leaning this heavily on one animal type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02One country drives the leading region
34% of the leading region is one country: China, at USD 0.74 billion against Asia Pacific's USD 2.19 billion in 2025, and USD 1.49 billion by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
5 axesfive segmentation axes are reported; by animal type, by vaccine type, disease/indication, route of administration and distribution channel. Revenue does not add across them: each is a different cut of the same total.
There are six lines on the animal type axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: two gain it, the rest give it up.
By Animal Type · 6 segments
Aquaculture Outpaces the Axis While Poultry Holds the Largest Share
- Largest Poultry · 34%
- Fastest Aquaculture · 11.1%
- Moves most Aquaculture · +3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Poultry | $2.33B | 34% | $4.12B | 33%-1 | 6.6% |
| Swine | $1.51B | 22% | $2.62B | 21%-1.1 | 6.4% |
| Cattle (Bovine) | $1.64B | 23.9% | $2.87B | 23%-0.9 | 6.5% |
| Sheep & Goat (Ovine/Caprine) | $0.55B | 8% | $1B | 8% | 7% |
| Aquaculture | $0.48B | 7% | $1.25B | 10%+3 | 11.1% |
| Other Livestock (Equine & Others) | $0.34B | 5% | $0.62B | 5% | 6.7% |
Poultry leads because global flocks are vaccinated on the shortest cycles of any livestock category, and mass immunization is standard practice against endemic diseases such as Newcastle disease and avian influenza. Aquaculture grows fastest as farmed fish and shrimp production expands and intensifies, raising disease pressure and encouraging a shift away from antibiotic use toward vaccination. Poultry remains the largest line through 2034, so the axis changes in proportion, not in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Vaccine Type · 5 segments
Live Attenuated Held the Dominant Share of the Vaccine type Segment in 2025
- Largest Live Attenuated · 38%
- Fastest DNA & Vector-based · 11.8%
- Moves most Recombinant / Subunit · +4.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Live Attenuated | $2.60B | 38% | $4.24B | 34%-4 | 5.6% |
| Inactivated / Killed | $2.33B | 34% | $3.99B | 32%-2 | 6.2% |
| Toxoid | $0.69B | 10.1% | $1.12B | 9%-1.1 | 5.5% |
| Recombinant / Subunit | $0.82B | 12% | $2B | 16%+4.1 | 10.4% |
| DNA & Vector-based | $0.41B | 6% | $1.12B | 9%+3 | 11.8% |
Live attenuated formulations lead because they remain the standard, cost-effective choice for large-scale herd and flock immunization against endemic viral disease. Recombinant, subunit and DNA or vector-based platforms grow fastest as regulators and integrators favor differentiable, needle-reduced formats that support disease surveillance and faster strain updates against emerging pathogens. By 2034 Live Attenuated is still ahead, making this a shift in weight, not a change of leader.
By Disease/indication · 5 segments
By Disease/indication
- Largest Avian Influenza & Newcastle Disease · 30%
- Fastest Porcine Reproductive & Respiratory Syndrome (PRRS) · 7.7%
- Moves most Foot-and-Mouth Disease · -2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Avian Influenza & Newcastle Disease | $2.06B | 30% | $3.99B | 32%+1.9 | 7.6% |
| Foot-and-Mouth Disease | $1.51B | 22% | $2.50B | 20%-2 | 5.8% |
| Bovine Respiratory Disease Complex | $1.23B | 17.9% | $2.12B | 17%-0.9 | 6.2% |
| Porcine Reproductive & Respiratory Syndrome (PRRS) | $1.03B | 15% | $2B | 16%+1 | 7.7% |
| Other Diseases | $1.03B | 15% | $1.87B | 15% | 6.9% |
Avian Influenza & Newcastle Disease Led by Disease/indication in 2025, with Porcine Reproductive & Respiratory Syndrome (PRRS) Growing Fastest Avian influenza and Newcastle disease vaccination leads because poultry flocks are vaccinated on the highest-frequency cycles of any livestock category, and outbreaks trigger immediate mass immunization mandates. PRRS vaccination grows fastest as swine operations raise biosecurity spending following recurrent regional outbreaks that have proven costly to unprotected herds. Avian Influenza & Newcastle Disease remains the largest line through 2034, so the axis changes in proportion, not in order.
By Route of Administration · 4 segments
Scale in Injectable and Growth in In-ovo Define the Route of administration Axis
- Largest Injectable · 58%
- Fastest In-ovo · 11.8%
- Moves most In-ovo · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Injectable | $3.97B | 58% | $6.86B | 55%-3 | 6.3% |
| Spray / Aerosol | $1.37B | 20% | $2.37B | 19%-1 | 6.3% |
| Oral | $0.96B | 14% | $1.75B | 14% | 6.9% |
| In-ovo | $0.55B | 8% | $1.50B | 12%+4 | 11.8% |
Injectable delivery leads because it remains the most reliable route for achieving consistent immune response across cattle, swine and small ruminants where handling permits individual dosing. In-ovo vaccination grows fastest as large-scale hatcheries adopt automated systems that cut labor cost and improve uniform coverage ahead of chick placement. Injectable remains the largest line through 2034, so the axis changes in proportion, not in order.
By Distribution Channel · 3 segments
Veterinary Hospitals & Clinics Held the Dominant Share of the Distribution channel Segment in 2025
- Largest Veterinary Hospitals & Clinics · 52%
- Fastest Online & Direct-to-Farm · 11.9%
- Moves most Online & Direct-to-Farm · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Veterinary Hospitals & Clinics | $3.56B | 52% | $6.12B | 49%-3 | 6.2% |
| Retail & Farm Supply Stores | $2.47B | 36.1% | $4.12B | 33%-3.1 | 5.8% |
| Online & Direct-to-Farm | $0.82B | 12% | $2.25B | 18%+6 | 11.9% |
Veterinary hospitals and clinics lead because most livestock vaccination is administered or prescribed under professional veterinary oversight, particularly for compulsory or outbreak-response campaigns. Online and direct-to-farm channels grow fastest as larger commercial operations increasingly order routine, non-controlled vaccines directly for on-site administration by trained farm staff. Veterinary Hospitals & Clinics remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The 2nd-largest region covered — 3 points of share move elsewhere by 2034.
- Rank 2 of 5
- 2025 share 24%
- By 2034 21%
- Revenue $1.64B → $2.62B
USD 1.64 billion of 2025 revenue is generated in North America, 24% of the global livestock vaccine market with USD 2.62 billion projected for 2034. It is a leading region on this axis, second by revenue throughout the period.
By 2034 the share stands at 21%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Within the region the animal type split tracks the global one; 34.01% of 2025 revenue in Poultry, fastest growth of 11.06% in Aquaculture. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 85% of it, growing 1.6×.
- In region 1 of 2
- Of region 85%
- Of global 20.3%
- Revenue $1.39B → $2.23B
85% of North America's base-year revenue comes from the United States; USD 1.39 billion, rising to USD 2.23 billion by 2034. Because it is 85% of the region in the base year, North America's totals move with this one country instead of a spread of them. The region itself runs USD 1.64 billion to USD 2.62 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Poultry at 34.01% of 2025 revenue, easing to 33.01% by 2034, and the fastest is Aquaculture at 11.06%, from 7.01% to 10.02%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-animal type revenue for the United States appears on its own in the full report.
Livestock vaccines in the United States fall under the Center for Veterinary Biologics at the Animal and Plant Health Inspection Service, part of the Department of Agriculture, a distinct track from the drug approvals the Food and Drug Administration handles. A manufacturer must hold an establishment licence and a product licence before any vaccine reaches the market, with each production batch subject to serial release testing for purity, safety and potency. Labelling must state the target species, indications, storage conditions and an expiry date, and any claim of efficacy must be backed by data submitted to the agency. Facilities are inspected on a recurring basis to confirm that production stays within the conditions under which the licence was granted. Combination and autogenous vaccines follow their own supplementary review paths within the same framework.
Supplier positions in the United States sit on the animal type axis: the country buys the same lines the global market does, in the same order. The commercially relevant division is 34.01% of 2025 revenue in Poultry, where the volume is, against 11.06% growth in Aquaculture, where share moves. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 1.6×.
- In region 2 of 2
- Of region 15%
- Of global 3.6%
- Revenue $0.25B → $0.39B
Within North America, Canada accounts for 15% of regional revenue and 3.65% of the global total, worth USD 0.25 billion in 2025 and USD 0.39 billion by 2034.
Europe Market Analysis
The 3rd-largest region covered — 3 points of share move elsewhere by 2034.
- Rank 3 of 5
- 2025 share 22%
- By 2034 19%
- Revenue $1.51B → $2.37B
In Europe, 22% of global revenue puts 2025 at USD 1.51 billion and reaches USD 2.37 billion by 2034. Among the five regions it ranks third by revenue in both years.
Share settles at 19% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Poultry leads here as it does globally, at 34.01% of 2025 revenue, and Aquaculture again grows fastest at 11.06%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.6×.
- In region 1 of 3
- Of region 28%
- Of global 6.1%
- Revenue $0.42B → $0.66B
28% of Europe's base-year revenue comes from Germany; USD 0.42 billion, rising to USD 0.66 billion by 2034. Its 28% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 1.51 billion in 2025 and USD 2.37 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in Germany follows the animal type mix reported at global level: Poultry is the largest line at 34.01% of 2025 revenue, moving to 33.01% by 2034, while Aquaculture grows fastest at 11.06% and takes its share from 7.01% to 10.02%. Its 28% weight in Europe means those movements carry straight into the regional totals. Per-animal type revenue for Germany appears on its own in the full report.
As a member state, Germany applies the European Union's veterinary medicines framework, with the Paul-Ehrlich-Institut acting as the national authority for immunological veterinary products alongside the European Medicines Agency for centrally authorised vaccines. A supplier must secure a marketing authorisation demonstrating quality, safety and efficacy before a livestock vaccine can be sold, and manufacturing sites must operate under Good Manufacturing Practice certified through routine inspection. Labelling and the accompanying package leaflet must identify the target species, withdrawal periods where relevant, storage instructions and batch identification. Pharmacovigilance obligations continue after authorisation, requiring the holder to report adverse events. Cross-border recognition within the bloc lets a product authorised elsewhere in the Union enter the German market through mutual recognition rather than a fully separate national review.
What separates suppliers in Germany is where they sit on the animal type axis, not which country they serve. Poultry, at 34.01% of 2025 revenue, is where the volume sits, and Aquaculture, growing at 11.06%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 1.51 billion in 2025 reaching USD 2.37 billion by 2034, 22% of global revenue at the start of that period.
France
2nd-largest in Europe, growing 1.6×.
- In region 2 of 3
- Of region 22%
- Of global 4.8%
- Revenue $0.33B → $0.52B
Within Europe, France accounts for 22% of regional revenue and 4.82% of the global total, worth USD 0.33 billion in 2025 and USD 0.52 billion by 2034.
United Kingdom
3rd-largest in Europe, growing 1.6×.
- In region 3 of 3
- Of region 18%
- Of global 3.9%
- Revenue $0.27B → $0.43B
Within Europe, the United Kingdom accounts for 18% of regional revenue and 3.94% of the global total, worth USD 0.27 billion in 2025 and USD 0.43 billion by 2034.
Asia Pacific Market Analysis
The largest region covered, and the one gaining the most — it picks up 3 points of share by 2034, while revenue still grows 2.0×.
- Rank 1 of 5
- 2025 share 32%
- By 2034 35%
- Revenue $2.19B → $4.37B
USD 2.19 billion of 2025 revenue is generated in Asia Pacific, 32% of the global livestock vaccine market and reaches USD 4.37 billion by 2034. That makes it the first-largest region covered, in 2025 and again in 2034.
Share climbs to 35% by 2034, because it outgrows the market's 6.93%; the revenue added here is disproportionate to where the region started.
Within the region the animal type split tracks the global one; 34.01% of 2025 revenue in Poultry, fastest growth of 11.06% in Aquaculture. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.0×.
- In region 1 of 3
- Of region 34%
- Of global 10.8%
- Revenue $0.74B → $1.49B
China is the largest market within Asia Pacific, generating USD 0.74 billion in 2025 and projected to reach USD 1.49 billion by 2034. Its 34% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 2.19 billion in 2025 and USD 4.37 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in China follows the animal type mix reported at global level: Poultry is the largest line at 34.01% of 2025 revenue, moving to 33.01% by 2034, while Aquaculture grows fastest at 11.06% and takes its share from 7.01% to 10.02%. Its 34% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own animal type breakdown in the full report.
China regulates livestock vaccines through the Ministry of Agriculture and Rural Affairs, with the China Institute of Veterinary Drug Control responsible for batch testing and technical review ahead of market entry. A supplier must obtain a veterinary biologics production licence and register each product before distribution, and every batch destined for sale is subject to mandatory lot release testing conducted by the institute rather than left to manufacturer self-certification. Labelling must be in Chinese and state the strain composition, target species, dosage and storage requirements. Domestic manufacturing facilities are inspected against national Good Manufacturing Practice standards, and imported vaccines face additional registration steps specific to foreign-produced biologics. State procurement programmes for certain epidemic-control vaccines run alongside the standard commercial approval route.
Competition in China is decided on the animal type axis rather than on geography, since suppliers here sell into the same animal type lines reported globally. Volume sits in Poultry at 34.01% of 2025 revenue; movement sits in Aquaculture at 11.06% growth. The commercial size of that position is USD 2.19 billion in 2025, moving to USD 4.37 billion by 2034 across the forecast period.
India
2nd-largest in Asia Pacific, growing 2.0×.
- In region 2 of 3
- Of region 22%
- Of global 7%
- Revenue $0.48B → $0.96B
7.01% of global revenue is generated in India; USD 0.48 billion in 2025, reaching USD 0.96 billion in 2034, and 22% of Asia Pacific.
Japan
3rd-largest in Asia Pacific, growing 2.0×.
- In region 3 of 3
- Of region 12%
- Of global 3.8%
- Revenue $0.26B → $0.52B
Japan is sized at USD 0.26 billion in 2025, rising to USD 0.52 billion by 2034; 3.8% of global revenue and 12% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered — it picks up 2 points of share by 2034, while revenue still grows 2.1×.
- Rank 4 of 5
- 2025 share 15%
- By 2034 17%
- Revenue $1.03B → $2.12B
15% of the global livestock vaccine market sits in Latin America in 2025, worth USD 1.03 billion and reaches USD 2.12 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
Its share rises to 17% over the forecast period, because it outgrows the market's 6.93%; the revenue added here is disproportionate to where the region started.
Within the region the animal type split tracks the global one; 34.01% of 2025 revenue in Poultry, fastest growth of 11.06% in Aquaculture. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 2.1×.
- In region 1 of 2
- Of region 55%
- Of global 8.3%
- Revenue $0.57B → $1.17B
Brazil is the largest market within Latin America, generating USD 0.57 billion in 2025 and projected to reach USD 1.17 billion by 2034. 55% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 1.03 billion in 2025 and USD 2.12 billion in 2034, it is the country the full report breaks out in detail.
The animal type pattern in Brazil is the global one: 34.01% of 2025 revenue in Poultry, 33.01% by 2034, against 11.06% growth in Aquaculture taking it from 7.01% to 10.02%. Since 55% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-animal type revenue for Brazil appears on its own in the full report.
The Ministry of Agriculture and Livestock, through its Department of Animal Health, governs the registration and oversight of livestock vaccines in Brazil. A supplier must register each product before sale, submitting data on composition, safety and efficacy specific to the target species and the disease it addresses. Manufacturing establishments require their own operating licence and are inspected against Good Manufacturing Practice standards particular to veterinary biologics. Labelling must appear in Portuguese and disclose the antigen composition, batch number, target species, storage conditions and any withdrawal period. Official batch release testing applies to certain vaccine categories before distribution is permitted. Import of foreign-manufactured vaccines follows a parallel registration route that still requires evidence generated under Brazilian conditions where the disease profile warrants it.
What separates suppliers in Brazil is where they sit on the animal type axis, not which country they serve. The commercially relevant division is 34.01% of 2025 revenue in Poultry, where the volume is, against 11.06% growth in Aquaculture, where share moves. The commercial size of that position is USD 1.03 billion in 2025 and USD 2.12 billion by 2034, 15% of the global total in the base year.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 22%
- Of global 3.4%
- Revenue $0.23B → $0.47B
Mexico is sized at USD 0.23 billion in 2025, rising to USD 0.47 billion by 2034; 3.36% of global revenue and 22% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 2.1×.
- Rank 5 of 5
- 2025 share 7%
- By 2034 8%
- Revenue $0.48B → $1B
Middle East and Africa holds 7% of the global livestock vaccine market in 2025, worth USD 0.48 billion rising to USD 1 billion in 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share has moved up to 8%, so the region grows faster than the market's 6.93% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Poultry leads here as it does globally, at 34.01% of 2025 revenue, and Aquaculture again grows fastest at 11.06%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.1×.
- In region 1 of 2
- Of region 30%
- Of global 2%
- Revenue $0.14B → $0.30B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.14 billion in 2025 and USD 0.3 billion in 2034. 30% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.48 billion in 2025 and USD 1 billion in 2034, it is the country the full report breaks out in detail.
Demand in Saudi Arabia follows the animal type mix reported at global level: Poultry is the largest line at 34.01% of 2025 revenue, moving to 33.01% by 2034, while Aquaculture grows fastest at 11.06% and takes its share from 7.01% to 10.02%. Its 30% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-animal type revenue for Saudi Arabia appears on its own in the full report.
Saudi Arabia regulates livestock vaccines through the Ministry of Environment, Water and Agriculture, working alongside the Saudi Food and Drug Authority on registration and quality oversight of veterinary biologics. A supplier must register a product before it can be marketed, with dossiers reviewed for composition, target species and manufacturing quality, and imported vaccines undergo additional customs and quarantine checks tied to the kingdom's animal health protections. Facilities supplying the market, whether domestic or foreign, must demonstrate conformity with recognised Good Manufacturing Practice standards. Labelling must appear in Arabic, stating the target species, storage conditions, batch identification and expiry information. Vaccines addressing diseases under national eradication or control programmes may face separate approval conditions set directly by the ministry.
Saudi Arabia does not have a competitive structure of its own; position here is position on the animal type axis reported above. Two different problems sit on the same axis: holding Poultry at 34.01% of 2025 revenue, and taking Aquaculture while it grows at 11.06%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.48 billion in 2025 reaching USD 1 billion by 2034, 7% of global revenue at the start of that period.
South Africa
2nd-largest in Middle East and Africa, growing 2.1×.
- In region 2 of 2
- Of region 25%
- Of global 1.8%
- Revenue $0.12B → $0.25B
1.75% of global revenue is generated in South Africa; USD 0.12 billion in 2025, reaching USD 0.25 billion in 2034, and 25% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Animal Type, Vaccine Type, Disease/Indication, Route of Administration, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Animal type Axis Decides Competitive Standing
The competitive line that matters is the animal type one, not the geographic one. Volume sits in Poultry, USD 2.33 billion and 34.01% of 2025 revenue, 33.01% by 2034, which is also where an incumbent is hardest to dislodge. Share moves in Aquaculture, growing 11.06% against 6.36% for Swine. Holding the first and taking the second are separate capabilities, which is why a market of USD 6.85 billion supports as many suppliers as it does.
Competition in livestock vaccines turns on manufacturing and formulation scale, since large-batch fermentation and antigen production capacity determines who can supply outbreak-driven demand spikes without delay. Regulatory and approval experience across multiple national veterinary authorities lets the largest suppliers launch a new antigen in many markets at once, while distribution reach into veterinary networks, farm cooperatives and integrated poultry and swine operations decides day-to-day volume. Smaller and regional suppliers compete instead on locally relevant disease strains, established government tender relationships, faster single-country registration and price positioning suited to smallholder and subsistence farming segments that larger multinational portfolios serve less directly.
Geographic reach is the other axis of competition. Asia Pacific alone accounts for 32% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; North America adds a further 24%.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Livestock Vaccine Market Companies Profiled
12 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Zoetis(United States)
- Boehringer Ingelheim(Germany)
- Merck Animal Health(United States)
- Ceva Sante Animale(France)
- Elanco Animal Health(United States)
- Virbac(France)
- HIPRA(Spain)
- Phibro Animal Health(United States)
- Indian Immunologicals Ltd(India)
- Biogenesis Bago(Argentina)
- Vetoquinol(France)
- IDT Biologika(Germany)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Animal Type, Vaccine Type, Disease/indication, Route of Administration, Distribution Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 12 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Livestock Vaccine Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Livestock Vaccine Market Overview, By Animal Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Livestock Vaccine Market Overview, By Vaccine Type, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Livestock Vaccine Market Overview, By Disease/indication, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Livestock Vaccine Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Livestock Vaccine Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Livestock Vaccine Market Size — Segment Comparison
Chapter 22.Global Livestock Vaccine Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Livestock Vaccine Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Livestock Vaccine Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Livestock Vaccine Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Livestock Vaccine Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Livestock Vaccine Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Animal Type
6- 01Poultry
- 02Swine
- 03Cattle (Bovine)
- 04Sheep & Goat (Ovine/Caprine)
- 05Aquaculture
- 06Other Livestock (Equine & Others)
By Vaccine Type
5- 01Live Attenuated
- 02Inactivated / Killed
- 03Toxoid
- 04Recombinant / Subunit
- 05DNA & Vector-based
By Disease/indication
5- 01Avian Influenza & Newcastle Disease
- 02Foot-and-Mouth Disease
- 03Bovine Respiratory Disease Complex
- 04Porcine Reproductive & Respiratory Syndrome (PRRS)
- 05Other Diseases
By Route of Administration
4- 01Injectable
- 02Spray / Aerosol
- 03Oral
- 04In-ovo
By Distribution Channel
3- 01Veterinary Hospitals & Clinics
- 02Retail & Farm Supply Stores
- 03Online & Direct-to-Farm
Segment categories shown for scope reference. See the Summary tab for revenue share by By Animal Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The market was built upward from unit dose volumes administered by animal category, poultry flocks, swine herds, cattle head counts, small ruminant populations and farmed aquatic species, multiplied by the realized price per dose for each vaccine platform. Dose volumes were derived from national livestock population counts and typical annual vaccination frequency per species and disease. That bottom-up build was then checked against disclosed farm-animal or livestock-vaccine segment revenue reported by major animal health companies. Where the two diverged, the correction was made to the bottom-up assumption, most often dosing frequency for a given species or the realized price for a vaccine platform, rather than averaging the build against the disclosed figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targeted commercial and regulatory managers at animal health companies, veterinary practitioners treating livestock herds and flocks, procurement heads at integrated poultry and swine operations, distributors serving farm cooperatives, and officials at government animal health agencies that run compulsory vaccination programs. These roles were chosen because each sees a different part of the same transaction: the company sets list price and platform strategy, the veterinary practitioner or farm manager decides dosing and timing, and the regulator sets which vaccines are mandatory. Sampling weighted toward the largest livestock-producing geographies: the United States, Germany and France within Europe, China, India and Brazil.
Desk research drew on national veterinary biologics registries, including the USDA Center for Veterinary Biologics licensed product list and the European Medicines Agency veterinary product register, to identify which vaccines are approved and by whom. WOAH (OIE) disease outbreak reporting was used to time outbreak-driven demand. Customs data under the relevant harmonized system codes for veterinary biological products informed cross-border trade volumes. Publicly disclosed segment revenue from major animal health companies' financial filings anchored the top-down check, and national livestock population data from FAO and USDA NASS supplied the dose-volume base for the bottom-up build.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected herd and flock population growth by region, the pace at which regulatory authorities add new mandatory vaccination requirements, and pricing behavior as vaccine platforms shift from conventional live and inactivated formulations toward recombinant, subunit and vector-based products that carry a higher per-dose price. One anomaly is normalized for: episodic outbreak-driven demand spikes, such as an avian influenza event, are smoothed into a steady baseline vaccination rate instead of being projected forward as a recurring annual surge. For the forecast to hold, livestock population growth and disease-control mandates need to continue at broadly their recent pace in the largest producing regions.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested against recorded revenue growth by animal category and region across 2020 to 2024 to confirm the bottom-up build reproduces already-known history before it is extended forward. Segment share shifts, such as the rising share of aquaculture and recombinant platforms, were reviewed against expert judgment on where vaccination intensity is genuinely increasing rather than where reporting has simply improved. Sensitivities were tested for slower-than-modeled aquaculture adoption, for delayed regulatory approval of newer vaccine platforms, and for a scenario in which disease outbreak frequency runs below its recent historical average.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is strongest for poultry and swine vaccination, where large integrated operations and major animal health companies report dose volumes and revenue with reasonable regularity. It is weaker for aquaculture and for small ruminant vaccination served through smallholder and subsistence farming, where reporting is thin and dosing is irregular enough that year-to-year figures are triangulated from adjacent proxies instead of direct disclosure. The clearest structural risk to this estimate is a major disease outbreak, which could pull a full year of vaccination demand into a single quarter well above the modeled baseline.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Livestock Vaccine Market projected to reach?
USD 12.48 Billion by 2034, CAGR 6.93%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
Asia Pacific leads with 32% of global revenue through 2034.
05Which segment leads the market?
Poultry is the largest line by Animal Type, at 34.01% of revenue in 2025.
06Who are the key companies profiled?
Zoetis, Boehringer Ingelheim, Merck Animal Health, Ceva Sante Animale, Elanco Animal Health, Virbac, HIPRA, Phibro Animal Health, Indian Immunologicals Ltd, Biogenesis Bago, Vetoquinol, IDT Biologika. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.